Photonics Control & Test Engineer

Xanadu and University of Alberta explore quantum computing for cancer drug discovery. Insider Brief * Xanadu Quantum Technologies and the University of Alberta have formed a research partnership to explore quantum algorithms for designing photosensitizers used in photodynamic cancer therapy. * The collaboration will combine Xanadu's quantum algorithm expertise with Professor Alex Brown's research in computational modeling of photosensitizer systems. * The research aims to investigate whether quantum computing can help model light-matter interactions involved in developing new cancer treatment compounds. Press release - Xanadu Quantum Technologies Limited ("Xanadu"; NASDAQ/TSX: XNDU), a leading photonic quantum computing company, and the University of Alberta, have announced a strategic research partnership to pioneer novel quantum algorithms for cancer treatment. This partnership, led by the Xanadu algorithms team and Professor Alex Brown from the University of Alberta, aims to develop a quantum computing framework that can accelerate the design of next-generation photosensitizers used in photodynamic therapy, a powerful, non-invasive therapeutic cancer treatment. Photodynamic cancer therapy uses light-activated compounds, called photosensitizers, to selectively destroy tumor cells, while avoiding the side effects of traditional cancer treatments, such as chemotherapy. However, discovering new and more effective photosensitizers can be difficult, as it requires either slow and costly experiments or classical simulations that don't take into account crucial interactions determining their effectiveness. Xanadu has recently released results pioneering the use of quantum computers to simulate important light-matter interactions in photosensitizers, which are critical for determining key properties that are difficult to predict using classical computational approaches. These include their sensitivity to specific wavelengths and their efficiency in triggering cancer cell death. Professor Brown has published highly influential work on benchmarking computational simulations of photosensitizer systems. By combining their expertise, Xanadu and Professor Brown aim to further explore how quantum computing can overcome classical computational challenges in photodynamic drug discovery. "Current methodologies for developing effective photosensitizers are hampered by a variety of hurdles. By leveraging early fault-tolerant quantum computers to model critical light-matter interactions within photosensitizers, we are positioning quantum computing as a highly competitive method for accelerating photodynamic drug discovery," said Dr. Christian Weedbrook, Founder and Chief Executive Officer of Xanadu. "Photosensitizers are challenging systems because their performance depends on excited-state processes that are difficult to capture accurately with standard computational methods. By combining Xanadu's quantum algorithm expertise with our experience in modeling photodynamic therapy systems, we're excited to explore how fault-tolerant quantum computing could provide new tools for understanding and designing more effective light-activated cancer treatments," said Professor Alex Brown, Professor and Chair of the Department of Chemistry, University of Alberta. This partnership aims to strengthen Xanadu's quantum-based workflow for drug design, expanding the framework to tackle increasingly sophisticated challenges in photosensitizer development. Professor Brown's contributions will be vital in identifying important mechanisms that determine therapeutic effectiveness. Together, Xanadu and University of Alberta will use quantum computing to push the boundaries of drug development and simulations for use in the pharmaceutical industry. Mohib ur rehman. Covering quantum and emerging technologies, Mohib explores the intersection of technology, security, and society. His work also frequently examines surveillance infrastructure and the institutions shaping the digital world. In addition to his work at The Quantum Insider, he co-runs SK NEXUS, an independent technology publication that helps readers understand the technologies shaping their lives. Stay Ahead of Quantum Get the latest research, company news, and market intelligence every week. MENTIONED IN THE ARTICLE More in Research

Xanadu Quantum Technologies shares dropped 8% on Thursday after the quantum computing firm's second-quarter revenue missed Wall Street expectations. The company reported revenue of $1.51 million, up 42.5% year-over-year but $0.49 million below consensus forecasts. Revenue also fell sequentially from $2.8 million in the first quarter. The company posted a GAAP loss of $0.14 per share, beating analyst estimates by $0.03. However, the quarterly net loss widened to $42.1 million from $20.6 million a year earlier as Xanadu increased investment in growth. Research and development spending rose to $19.7 million, whilst capital expenditures reached $6.4 million. Xanadu ended the quarter with $312.8 million in cash after raising $67.2 million through its $300 million synthetic at-the-market equity facility.

Xanadu Quantum Technologies reported $312.8 million in cash reserves to fund its quantum computing development. The company raised an additional $67.2 million this quarter through a facility with Yorkville Advisors, selling 5.5 million shares at an average net price of $12.28. The firm achieved 0.085 decibel edge-coupling loss in its photonic chips, a significant reduction in signal degradation. Foundry fabrication of thin-film lithium niobate increased approximately 75%, whilst silicon nitride production rose roughly 50%. Xanadu expanded its US headcount more than five-fold since 2023. Research and development expense reached $19.7 million, up $2.4 million from the previous quarter, primarily due to engineering hires. The company developed a Quantum Read-Only Memory algorithm that cuts required Toffoli gate operations by approximately half.